137 related articles for article (PubMed ID: 11911422)
1. Immunophenotype changes and loss of CD52 expression in two patients with relapsed T-cell prolymphocytic leukaemia.
Tuset E; Matutes E; Brito-Babapulle V; Morilla R; Catovsky D
Leuk Lymphoma; 2001; 42(6):1379-83. PubMed ID: 11911422
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H.
Birhiray RE; Shaw G; Guldan S; Rudolf D; Delmastro D; Santabarbara P; Brettman L
Leukemia; 2002 May; 16(5):861-4. PubMed ID: 11986948
[TBL] [Abstract][Full Text] [Related]
3. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody.
Pawson R; Dyer MJ; Barge R; Matutes E; Thornton PD; Emmett E; Kluin-Nelemans JC; Fibbe WE; Willemze R; Catovsky D
J Clin Oncol; 1997 Jul; 15(7):2667-72. PubMed ID: 9215839
[TBL] [Abstract][Full Text] [Related]
4. Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H.
Ginaldi L; De Martinis M; Matutes E; Farahat N; Morilla R; Dyer MJ; Catovsky D
Leuk Res; 1998 Feb; 22(2):185-91. PubMed ID: 9593475
[TBL] [Abstract][Full Text] [Related]
5. CD52 expression in T-cell large granular lymphocyte leukemia--implications for treatment with alemtuzumab.
Osuji N; Del Giudice I; Matutes E; Morilla A; Owusu-Ankomah K; Morilla R; Dunlop A; Catovksy D
Leuk Lymphoma; 2005 May; 46(5):723-7. PubMed ID: 16019510
[TBL] [Abstract][Full Text] [Related]
6. T-cell prolymphocytic leukemia.
Dearden CE
Med Oncol; 2006; 23(1):17-22. PubMed ID: 16645226
[TBL] [Abstract][Full Text] [Related]
7. T-cell receptor gammadelta T-cell leukemia with the morphology of T-cell prolymphocytic leukemia and a postthymic immunophenotype.
Sugimoto T; Imoto S; Matsuo Y; Kojima K; Yasukawa M; Murayama T; Kohfuku J; Mizuno I; Yakushijin K; Sada A; Nishimura R; Koizumi T
Ann Hematol; 2001 Dec; 80(12):749-51. PubMed ID: 11797117
[TBL] [Abstract][Full Text] [Related]
8. T-cell prolymphocytic leukemia: an aggressive T cell malignancy with frequent cutaneous tropism.
Magro CM; Morrison CD; Heerema N; Porcu P; Sroa N; Deng AC
J Am Acad Dermatol; 2006 Sep; 55(3):467-77. PubMed ID: 16908353
[TBL] [Abstract][Full Text] [Related]
9. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
10. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
11. Trisomy 8q due to i(8q) or der(8) t(8;8) is a frequent lesion in T-prolymphocytic leukaemia: four new cases and a review of the literature.
Mossafa H; Brizard A; Huret JL; Brizard F; Lessard M; Guilhot F; Tanzer J
Br J Haematol; 1994 Apr; 86(4):780-5. PubMed ID: 7918072
[TBL] [Abstract][Full Text] [Related]
12. The effects of CAMPATH-1H on cell viability do not correlate to the CD52 density on the cell surface.
Lee F; Luevano M; Veys P; Yong K; Madrigal A; Shaw BE; Saudemont A
PLoS One; 2014; 9(7):e103254. PubMed ID: 25050704
[TBL] [Abstract][Full Text] [Related]
13. Seropositive polyarthritis and skin manifestations in T-prolymphocytic leukemia/Sezary cell leukemia variant.
Dybjer A; Hellquist L; Johansson B; Rydgren L; Billström R
Leuk Lymphoma; 2000 Apr; 37(3-4):437-40. PubMed ID: 10752996
[TBL] [Abstract][Full Text] [Related]
14. CD52 expression in hairy cell leukemia.
Quigley MM; Bethel KJ; Sharpe RW; Saven A
Am J Hematol; 2003 Dec; 74(4):227-30. PubMed ID: 14635201
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab].
Fløisand Y; Brinch L; Gedde-Dahl T; Tjønnfjord GE
Tidsskr Nor Laegeforen; 2004 Mar; 124(6):768-70. PubMed ID: 15039804
[TBL] [Abstract][Full Text] [Related]
16. Sezary cell leukaemia: a distinct T cell disorder or a variant form of T prolymphocytic leukaemia?
Pawson R; Matutes E; Brito-Babapulle V; Maljaie H; Hedges M; Mercieca J; Dyer M; Catovsky D
Leukemia; 1997 Jul; 11(7):1009-13. PubMed ID: 9204983
[TBL] [Abstract][Full Text] [Related]
17. CD52 expression in mantle cell lymphoma.
Bass AJ; Gong J; Nelson R; Rizzieri DA
Leuk Lymphoma; 2002 Feb; 43(2):339-42. PubMed ID: 11999566
[TBL] [Abstract][Full Text] [Related]
18. Mutations in PIGA cause a CD52-/GPI-anchor-deficient phenotype complicating alemtuzumab treatment in T-cell prolymphocytic leukemia.
Johansson P; Klein-Hitpass L; Röth A; Möllmann M; Reinhardt HC; Dührsen U; Dürig J
Eur J Haematol; 2020 Dec; 105(6):786-796. PubMed ID: 32875608
[TBL] [Abstract][Full Text] [Related]
19. CD52 as a molecular target for immunotherapy to treat acute myeloid leukemia with high EVI1 expression.
Saito Y; Nakahata S; Yamakawa N; Kaneda K; Ichihara E; Suekane A; Morishita K
Leukemia; 2011 Jun; 25(6):921-31. PubMed ID: 21394097
[TBL] [Abstract][Full Text] [Related]
20. Masquerade syndrome: T-cell prolymphocytic leukemia presenting as panuveitis.
Dhar-Munshi S; Alton P; Ayliffe WH
Am J Ophthalmol; 2001 Aug; 132(2):275-7. PubMed ID: 11476701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]